US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Biodesix, Inc. - Common Stock (NQ:BDSX)

27.72 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biodesix, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Participate in Two Upcoming Investor Conferences in September
From Biodesix, Inc.
Via Business Wire
News headline image
Recap: Biodesix Q1 Earnings ↗
 
Via Benzinga
News headline image
Biodesix Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Kingstone Companies And 3 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces Second Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
News headline image
Top 5 Health Care Stocks That May Crash In Q3 ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
From Biodesix, Inc.
Via Business Wire
News headline image
Why Shares of CareDx Are Jumping Friday ↗
The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
From Biodesix, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! 
Via InvestorPlace
News headline image
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix Announces First Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
From Biodesix, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
From Biodesix, Inc.
Via Business Wire
News headline image
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Biodesix, Inc.
Via Business Wire
News headline image
Over $12 Million Bet On TD Holdings? Check Out These 3 Penny Stocks Insiders Are Buying ↗
The Federal Reserve on Wednesday raised its benchmark rate by 0.25%, marking the central bank's second consecutive policy downshift. When insiders purchase or sell shares, it indicates their confidence... 
Via Benzinga
News headline image
Looking Into Biodesix's Recent Short Interest ↗
Biodesix's (NASDAQ:BDSX) short percent of float has risen 67.65% since its last report. The company recently reported that it has 347 thousand shares sold short, which is 0.57% of all regular shares... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >